Download - Neuro Psycad
Supporting early and accurate diagnosis in neuropsychiatry
www.neuropsycad.com | [email protected]
Clinical history and observation is subjective.
Neuropsychiatric illnesses are the most frequent and debilitating.
Delayed DiagnosisDelayed TreatmentUnnecessary costs
Subtle brain changes are missed.
Brain scan examination depends on eye-inspection and memory.
?
With NeuroPsyCAD, clinicians send us the brain scan...
…we use artificial intelligence to compare it to a patients’ database…
... and provide a report (in hours) for early and accurate diagnosis.
Early disease management
Slowed disease progression
?Lower healthcare costs
REPORT on Patient X:
Alzheimer’s disease: 93%Mild cognitive impairment: 7%
Model: 94% accuracy (94% sensitivity; 95% specificity)
AI platform for Image Recognition of Neuropsychiatric Disorders
Capitalization on scan’sinformation
No other exams
Software for analysis of volume of single areas to aid diagnosis
‘Big Data’
61% 94%54% more accurate
Alzheimer’s
Parkinson’s
5x cheaper
€1500 €300
Served market ~1.62 M new patients/year (EU/USA); B2B to hospitals, clinics, insurance
Hugo FerreiraMSc Physics, MSc Medicine, PhD
Assistant Professor @FCUL
Lead and manages neuroimaging research group.
Over €500k raised.
Diana PrataMSc Biology, PhD
Group Leader @iMM, KCL
Leads and manages neuroscience research group.
Over €1.2M raised.
Ricardo MaximianoMSc Biomedical Eng
PhD Student @FCUL
Developed NeuroPsyCAD alpha-prototypes using
machine learning.
2017: 100K Investment, Caixa Capital
2016: ‘InovPortugal New Ideas B2B’ Award, Acredita Portugal
2016: Idea Prize to 10 best startup ideas, Born From Knowledge
Clinical Partners Advisory Board Database increase for model validationUser-experienceClinical trial for certification FDA/CE Prof Ray Chaudhuri (UK) - Parkinson’s
Prof Joaquim Ferreira (Portugal) - Parkinson’s
Prof Hilkka Soininen (Finland) - Alzheimer’s
Prof Sir Robin Murray (UK) - Schizophrenia
Key opinion leaders
Milestones – 1st year (Parkinson’s & Alzheimer’s)
1. Algorithm validation With larger online databases With new hospital databases
2. Clinical field trial Set up clinical partnerships Diagnostic models User portal and user experience
3. IP & Regulation IP strategy Certification (device class 2)
Feedback from users
Certification submission
MONTH 1 MONTH 4 MONTH 8 MONTH 12
Diagnostic models
User Portal IP strategy defined
Gap analysis
Shareholders and pre-seed investors
Use of 100k euros Caixa Capital Investment
Caixa Empreender Award
Faster algorithm validation
Faster database increase
Expansion to psychiatry
FDA / CE certification
+
Merger & Acquisition• Large healthcare IT companies (e.g. Cerner, Glintt, IBM, Google)• Scanner vendors (e.g. Siemens, General Electrics, Philips)• Data storage and Teleradiology companies (e.g. Sectra, Fujifilm, Ramsoft)• Similar companies (e.g. Cortechs Labs, Ixico)
Initial Public Offering (IPO)
Change of Market• Pharma (for clinical trials)• Academic Research (for neuroimaging analysis)• Database curation (for researchers, pharma or similar companies)
Closure
Exit
Supporting early and accurate diagnosis in neuropsychiatry
www.neuropsycad.com | [email protected]